SAN DIEGO, May 28, 2025 – Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that Capstan management will participate in the upcoming Jefferies Global Healthcare Conference 2025, being held between June 3–5, 2025 at the Marriott Marquis in New York, NY. Capstan management will be hosting one-on-one meetings with investors at the conference.

About Capstan Therapeutics, Inc. (www.capstantx.com)

Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody, that deliver an RNA payload capable of reprogramming cells in vivo. Capstan’s initial focus is on developing in vivo CAR-T therapies designed to combine the potency of CAR-T therapy with the convenience of a biologic, for the treatment of autoimmune diseases. For more information, please visit www.capstantx.com and follow us on LinkedIn.

Investors:
Miguel Arcinas
Senior Vice President of Corporate Development
Capstan Therapeutics, Inc.
ir@capstantx.com

Media:
Rhiannon Jeselonis
Ten Bridge Communications
capstan@tenbridgecommunications.com